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PREVALENCE OF UNDERLYING RISK FACTORS AMONG CHILDREN  
 
WITH ALL-CAUSE PNEUMONIA IN AN URBAN SETTING 
 
 
HANSOL CHUNG 
 
ABSTRACT 
  
Background: After the introduction of PCV7 and PCV13, the number of cases of 
pneumonia in children caused by vaccine serotypes has decreased significantly. Children 
with comorbidities, however, are still at high risk for IPD. This study aims to compare 
children with comorbidities to healthy children in an urban setting to assess current risk 
factors and potential risk factors for pneumonia. 
Methods: Existing clinical data of Boston Medical Center patients under 7 years of age 
were used to compare age, gender, race, comorbidities, and immune status of children 
with pneumonia to those of children without pneumonia. A representative random sample 
of 150 patients with pneumonia and 150 patients without pneumonia was selected. 
Medical record and chart information were reviewed in order to obtain clinical and 
demographic data.  
Results: In our study cohort, 120 of 300 (40%) children whose charts were reviewed had 
at least one comorbidity. Among 150 children with pneumonia, 76 (50.7%) cases were 
found to have at least one underlying condition, whereas in children without pneumonia 
44 (29.3%) of 150 cases had at least one underlying clinical condition (χ2 value 14.2; p-
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value <0.001). Children with comorbidities were 2.47 times more likely to have 
pneumonia compared to children without any chronic conditions (OR 2.47, 95% CI 1.54 
– 3.98). The risk of having pneumonia among children who are not 
Hispanic/Latino/Spanish was approximately 40% less compared to children of Hispanic 
origin (OR 0.61; 95% CI 0.31 – 1.19; p-value 0.14). 
Conclusions: Our study shows that children with underlying conditions are at greater risk 
for pneumonia compared to healthy children without chronic conditions. Ethnicity is also 
associated with pneumonia cases, with Hispanic children at increased risk for pneumonia 
compared to non-Hispanic children.  
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INTRODUCTION 
 
 Streptococcus pneumoniae (pneumococcus) is a major bacterial pathogen causing 
significant mortality and morbidity in children and adults worldwide, responsible for life-
threatening invasive diseases such as bloodstream infections (sepsis and bacteremia), 
pneumonia and meningitis. (Center for Disease Control and Prevention (CDC), 2010; 
Hausdorff, Feikin, & Klugman, 2005; Muñoz-Almagro et al., 2008) Pneumococcus is 
also a major cause of milder upper respiratory infections such as acute otitis media 
(AOM) and sinusitis, adding to the considerable disease burden and the occasional long 
term or suppurative sequelae. (Center for Disease Control and Prevention (CDC), 2010; 
Hausdorff et al., 2005; Muñoz-Almagro et al., 2008) Because of the high incidence and 
aggressive antibiotic treatment of AOM, pneumococcus has emerged as multidrug 
resistant in many countries. (Center for Disease Control and Prevention (CDC), 2010; 
Hausdorff et al., 2005; Muñoz-Almagro et al., 2008) Incidence of pneumococcal disease 
is particularly higher in young children and elderly people, resulting in nearly 1 million 
deaths in children under 5 years of age, annually. (Hicks et al., 2007; World Health 
Organization (WHO), 2007) In the USA, approximately 40,000 deaths occur as a result 
of pneumococcal pneumonia or meningitis, mostly in the elderly. (Bogaert, de Groot, & 
Hermans, 2004; Obaro & Adegbola, 2002) 
The major ecological niche of the pneumococcus is the nasopharynx of healthy 
children, and in order for invasive pneumococcal disease (IPD) to develop, colonization 
of S. pneumoniae in the nasopharynx is considered a required step. (Obaro & Adegbola, 
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2002; Sabharwal, Ram, Figueira, Park, & Pelton, 2009; Yildirim et al., 2010) 
Colonization of the S. pneumoniae in the nasopharynx is especially common in young 
children, and nasopharyngeal colonization occurs in most children in their first few years 
of life, with the highest level of colonization occurring at age 3. (Bogaert et al., 2004; 
Yildirim et al., 2010) Not all colonization leads to IPD or disease. Among the over 90 
pneumococcal serotypes identified, only 23 serotypes are responsible for the majority of 
the IPD cases. In North America, 7 serotypes were responsible for 80% of the IPD cases 
before the implementation of conjugated pneumococcal vaccines (4, 6B, 9V, 14, 18C, 
19F, and 23F). (Muñoz-Almagro et al., 2008) These serotypes that were dominant as 
causes of IPD are thought to possess properties that allow higher chances of invasion. 
Some of the serotypes, for example, may be carried at higher rates compared to other 
serotypes, increasing the likelihood of invasion. (Hausdorff et al., 2005; Yildirim et al., 
2010) In order to cause IPD, it is critical for the serotypes to possess capsular 
polysaccharides to evade host defense mechanisms such as complement-mediated 
opsonization and phagocytosis. (Sabharwal, Ram, Figueira, Park, & Pelton, 2009) This 
ability to avert host defenses may also be more effective in some serotypes, causing them 
to be more virulent than others. (Yildirim et al., 2010) 
 
7-Valent Pneumococcal Conjugate Vaccine (PCV7) 
In February 2000, 7-valent pneumococcal conjugate vaccine (PCV7) was 
introduced in the United States, licensed by the Food and Drug Administration (FDA) for 
use in infants and young children. (Center for Disease Control and Prevention (CDC), 
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2010) The vaccine works by triggering immune responses to the capsular 
polysaccharides, which is a critical component of invasive serotypes necessary to evade 
host defenses. (Hausdorff et al., 2005) The adult formulation (pneumococcal 
polysaccharide vaccine) is composed of polysaccharides from 23 serotypes that 
contribute predominantly to IPD; the polysaccharides trigger B cells to produce 
polysaccharide specific antibodies. (Hausdorff et al., 2005) In young children and infants 
where B cells are immature, polysaccharides from 7 to 11 of the most invasive serotypes 
must be linked to carrier proteins to enable them to engage T cells to achieve a protective 
immune response. (Hausdorff et al., 2005)  
Since the introduction of PCV7, which included the 7 most common serotypes 
causing IPD in Northern America (4, 6B, 9V, 14, 18C, 19F, and 23F), invasive diseases 
caused by vaccine serotypes declined by more than 99% in children under 5 years of age, 
resulting in a 75% decline in overall IPD. This represented a combination of the direct 
effect in vaccine recipients and the herd benefit in unvaccinated children. (Center for 
Disease Control and Prevention (CDC), 2005; Simonsen et al., 2011; Whitney et al., 
2003) Prior to PCV7 immunization, approximately 65,000 cases of IPD occurred 
annually in children under 5 years of age. (Tamara Pilishvili et al., 2010; Yildirim et al., 
2010) According to a study by Whitney et al. (2003), the largest decline occurred among 
children under 2 years of age, decreasing by 69% in 2001. Simonsen et al. (2011) 
reported a decrease in IPD and hospitalization and deaths associated with pneumococcal 
pneumonia in all age groups, including a decline by 47% in nonbacteremic pneumococcal 
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pneumonia in children under 2 years of age, and a 54% decrease in adults ≥65 years of 
age.  
Studies have also demonstrated that IPD in young children and adults caused by 
antibiotic-resistant strains decreased after PCV7 introduction. (Center for Disease Control 
and Prevention (CDC), 2010; Kyaw et al., 2006) Of the seven serotypes in PCV7, five 
serotypes (6B, 9V, 14, 19F, and 23F) were responsible for nearly 80% of the penicillin-
nonsusceptible isolates before PCV7, making the treatment for IPD more difficult. 
(Center for Disease Control and Prevention (CDC), 2010) After PCV7, however, rates of 
IPD caused by penicillin-nonsusceptible strains decreased by 81% among children under 
2 years of age, and 57% overall. (Center for Disease Control and Prevention (CDC), 
2010; Kyaw et al., 2006) 
 
Non-Vaccine Serotype Invasive Pneumococcal Disease 
 Rates of IPD caused by vaccine serotypes have declined significantly after routine 
vaccination of children with PCV7, but an increase in incidence of IPD caused by non-
vaccine serotypes has been reported in recent studies. This rise in incidence of 
pneumococcal diseases due to non-vaccine serotypes, known as the “replacement 
disease”, has been observed in all age groups. (Huang et al., 2009; Tamara Pilishvili et 
al., 2010) A study by Hicks et al. (2007) reported an increase in IPD cases caused by non-
vaccine serotypes from 17% of total cases prior to PCV7, to 88% of the cases in 2004. 
(Figure 1) Of the non-vaccine serotypes causing IPD, serotype 19A was reported to have 
increased most significantly after PCV7, emerging as the most prevalent serotype in all 
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age groups. (Table 1) (Hicks et al., 2007; Pelton et al., 2007; Tamara Pilishvili et al., 
2010) This occurred as PCV7 does not provide cross-protection against 19A even though 
19A is in the same serogroup as 19F, which is included in PCV7. (Moore et al., 2008) 
 Studies have suggested many possible explanations for the prevalence of serotype 
19A in children after PCV7 introduction. First, serotype 19A was present in the 
community before introduction of PCV7 in children under 5 years of age in the United 
States. (Hicks et al., 2007; Moore et al., 2008) Therefore, after the reduction of PCV7 
vaccine serotypes, serotype 19A has become the predominant serotype causing IPD in 
children. Second, studies have shown that serotype 19A is often nonsusceptible to 
antibiotics, complicating treatments. (Moore et al., 2008; Pelton et al., 2007) Third, the 
polysaccharide capsule of serotype 19A may enable these pneumococci to avert host 
defenses, making it more invasive than other serotypes. (Hicks et al., 2007) Lastly, 
through capsular switching, PCV7 vaccine serotypes (specifically type 4 and type 19F) 
may acquire a 19A polysaccharide capsule to escape the impact of PCV7. (Hicks et al., 
2007)  
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Figure 1.  Rates of invasive pneumococcal disease among children aged <5 years (A) 
and adults aged ≥65 years (B). (Figure taken from Hicks et al., 2007) An increase in 
IPD cases caused by non-vaccine serotypes is observed after PCV7 introduction in both 
adults ≥65 years and children <5 years. 
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Table 1. Changes in Incidence of Invasive Pneumococcal Disease, by Age Group and 
Serotype, 1998 – 1999 Average (Baseline) versus 2007. (Table taken from Tamara 
Pilishvili et al., 2010). 
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13-Valent Pneumococcal Conjugate Vaccine (PCV13) 
 Following widespread uptake of PCV7, the epidemiology of S. pneumoniae has 
evolved with an increase in IPD caused by serotypes not included in PCV7 (replacement 
disease), leading to the introduction of a second generation 13-valent conjugate vaccine 
(PCV13) targeting six additional serotypes in 2010. In February 2010, PCV13 was 
approved by FDA for use in young children and infants aged 6 weeks to 71 months. 
(Center for Disease Control and Prevention (CDC), 2010) In PCV13, six more serotypes 
(1, 3, 5, 6A, 7F, and 19A) that either became more prevalent after PCV7 [serotype 7, 
19A, 3, 6A] or were of importance globally [serotype 1, 5], were added to the previous 
seven serotypes included in PCV7. (Center for Disease Control and Prevention (CDC), 
2010) Prior to PCV13, the PCV13 vaccine serotypes were responsible for 61% of IPD 
cases in children under 5 years of age in 2008, while PCV7 serotypes accounted for less 
than 2% of IPD cases. (Center for Disease Control and Prevention (CDC), 2010) A study 
done by Loughlin et al. (2014) in Massachusetts reported a 74% decrease in PCV13 
colonization in vaccinated children when compared to unvaccinated children. The study 
also reported a 50% decrease of colonization in unvaccinated children, which provides 
evidence of indirect effect of PCV13. 
 
Risk Factors for Invasive Pneumococcal Disease before PCV7 
 There are numerous factors that increase the risk of developing IPD. Studies show 
that some of the most significant factors include: age groups, racial and ethnic groups, 
comorbidities, and children who attend group childcare. (Center for Disease Control and 
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Prevention (CDC), 2010; Loughlin, Hsu, Silverio, Marchant, & Pelton, 2014; Tamar 
Pilishvili et al., 2010; Robinson et al., 2001; Yildirim et al., 2014) Children and infants, 
especially those who are under 2 years of age and children ages 2-4 years, are at higher 
risk of developing IPD than others. (Tamar Pilishvili et al., 2010; Robinson et al., 2001; 
Yildirim et al., 2014) Elderly people are also at high risk for IPD; individuals aged ≥65 
years account for 56% of all deaths caused by IPD, and studies have reported an increase 
in rates of IPD of individuals aged ≥65 years with increasing age. (Robinson et al., 2001)  
 Certain racial and ethnic groups are also at higher risk for IPD compared to 
others. Studies have reported higher rates of IPD cases occurring among blacks, 
American Indians and Alaska Natives. (Center for Disease Control and Prevention 
(CDC), 2010; Robinson et al., 2001) A study involving populations in metropolitan 
Atlanta and Baltimore reported that incidence of IPD in black adults aged 18-64 years is 
5 to 8 times higher compared to other racial groups. (Nuorti et al., 2000) Another study 
by Robinson et al. (2001) reported that incidence rates among blacks were 2.6 times 
higher compared to those among whites of all ages. Despite the clear disparity present 
among racial groups, the reason behind the racial differences is not fully understood. 
(Robinson et al., 2001) 
 Children who attend day care are at higher risk for IPD than those who do not, 
because those who attend day care come in contact with other children from different 
environments, exposing them to a higher number of pneumococcal serotypes. (Levine et 
al., 1999) Among children who attended day care, highest incidence of IPD occurred 
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among those who attended for more than 10 hours per week, during the first 6 months of 
attending day care. (Table 2) (Tamar Pilishvili et al., 2010) 
 Among children diagnosed with IPD, studies show a higher proportion of children 
with underlying illnesses compared to healthy children. (Center for Disease Control and 
Prevention (CDC), 2010; Levine et al., 1999; Tamar Pilishvili et al., 2010; Yildirim et al., 
2014) Tamar Pilishvilli et al. (2010) reported a nearly 3-fold increase in presence of 
underlying conditions among those with IPD compared to those without IPD, and a study 
by Yildirim et al. (2014) reported a nearly 50-fold increase in risk for IPD in children 
with sickle cell disease and a nearly 33-fold increase in those with hematological 
malignancies. Most common comorbid illnesses present in those diagnosed with IPD 
include: congenital heart disease, immunodeficiency, HIV infection, cancer, nephritic 
syndrome, renal failure, asthma, functional or anatomic asplenia, and systemic steroid 
use. (Center for Disease Control and Prevention (CDC), 2010; Levine et al., 1999; Tamar 
Pilishvili et al., 2010)  
 Other factors that have been associated with high incidence of IPD are household 
exposure to smoking and the absence of breastfeeding. (Tamar Pilishvili et al., 2010)  
Among those who are breastfed, children particularly aged 2 to 11 months who are 
currently breastfed or have stopped within a month of the study had much lower rates of 
IPD. (Table 2) (Levine et al., 1999; Tamar Pilishvili et al., 2010) Reductions in IPD 
incidence among children who are currently breastfed are not fully understood, but they 
may be due to transfer of antibodies to certain serotypes or due to the ability of human 
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milk to reduce colonization of bacteria. (Andersson, Porras, Hanson, Lagergård, & 
Svanborg-Edén, 1986; Levine et al., 1999) 
Exposure to cigarette smoking was also strongly associated with IPD incidence. 
Studies report a higher incidence of IPD among active smokers and passive smokers, and 
rates of IPD were higher for active smokers compared to passive smokers. (Nuorti et al., 
2000) For healthy adults aged 18 to 64 years, cigarette smoking is considered the 
strongest independent risk factor for IPD, with the risk for IPD increasing by 51% for 
active smokers and 17% for passive smokers. (Nuorti et al., 2000) Among children with 
no underlying illnesses, those who were exposed to household smoking accounted for 9% 
of the non-PCV7 type IPD. (Tamar Pilishvili et al., 2010) Increases in IPD rates among 
active smokers or passive smokers may be due to the increased likelihood of developing 
respiratory infections or other illnesses that may increase the risk for IPD. (Nuorti et al., 
2000) In addition, studies have reported an increase in nasopharyngeal colonization 
among active and passive smokers. (Nuorti et al., 2000)  
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Table 2. Comparison of Demographic and Environmental Characteristics of Case 
Patients and Control Subjects. Table taken from Tamar Pilishvili et al. (2010).
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Changes in Risk Factors for IPD in the Era of PCV 
 A major change after PCV7 introduction was the elimination of the racial 
disparity in PCV7 type IPD, especially in children under 2 years of age. (Figure 2) 
(Talbot et al., 2004) According to Talbot et al. (2004), the rate of IPD cases in black 
children under 2 years of age decreased by 83%, reaching the rate of IPD cases in white 
children after PCV7 introduction. Talbot et al. also noted a decrease in the gap between 
the proportion of antibiotic nonsusceptible pneumococcal strains in white and black 
children under 2 years of age. In addition, among children vaccinated with one or more 
doses of PCV7, day care attendance no longer affected the rates of IPD caused by PCV7 
serotypes. (Tamar Pilishvili et al., 2010) Children with chronic underlying conditions, 
however, still remained at high risk for IPD. Compared to the effectiveness of PCV7 in 
preventing IPD in healthy children (94%), the effectiveness was much lower among those 
with underlying conditions (86%). (Tamar Pilishvili et al., 2010) In addition, children 
with medical conditions were at higher risk of developing IPD caused by less invasive 
serotypes (32.1%), compared to healthy children (18.3%), suggesting that serotypes that 
are less virulent and thus not included in PCV vaccines can be prevalent pathogens in 
children with comorbidities. (Yildirim et al., 2014) 
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Figure 2.  Annual Incidence Rates of Invasive Pneumococcal Disease in Tennessee 
by Race and Age Strata. Figure taken from Talbot et al. (2004). PCV7 was introduced 
in 2000. Racial disparity between black and white children decreases after 2000, more 
significantly among children under 2 years of age.  
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Minority Children in Urban Settings 
 Minority populations in the United States include blacks, Hispanics, Asians, 
Native Americans, and Pacific Islanders. (National Heart, Lung, and Blood Institute 
(NHLBI), 1995) Studies have shown generally larger rates of respiratory diseases in 
minority populations compared to white population, creating racial disparity in 
respiratory diseases including IPD. (National Heart, Lung, and Blood Institute (NHLBI), 
1995; Talbot et al., 2004) According to a report by the National Foundation for Infectious 
Diseases and the National Coalition for Adult Immunization (2002), minority populations 
may be more susceptible to pneumococcal diseases due to low immunization rates. 
Although pneumococcal vaccination has increased for the past ten years, a wide racial 
gap still exists between whites and other races, particularly in adults ≥65 years. (Figure 3) 
(National Foundation for Infectious Diseases & National Coalition for Adult 
Immunization, 2002) According to the study, minority populations have lower income, 
lower level of education, and are less likely to be insured compared to whites. In addition, 
the study suggests that language barriers and cultural differences may also prevent 
minority populations from receiving routine vaccination, making them more susceptible 
to pneumococcal diseases.  
 Children living in areas with high population density are more exposed to 
pneumococcal bacteria, making them more susceptible to nasopharyngeal colonization, 
compared to those who live in rural areas. (Venetz, Schopfer, & Mühlemann, 1998) 
Children in rural areas are also more likely to carry penicillin-nonsusceptible serotypes. 
(Lee et al., 2001; Schultsz et al., 2007) 
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Figure 3. U.S. Pneumococcal Vaccination Coverage Levels: Persons Aged 65 and 
Older. Figure taken from National Foundation for Infectious Diseases and the National 
Coalition for Adult Immunization (2002). Figure shows an increase in vaccination rates 
for all races, but a wide racial gap between whites and other races still exists. 
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Objective of the Research Study 
 Studies have shown that minority children and children in urban settings in 
particular are at higher risk for pneumococcal diseases, due to low immunization rates 
and higher exposure and transmission of the pneumococci. (Lee et al., 2001; National 
Foundation for Infectious Diseases & National Coalition for Adult Immunization, 2002; 
National Heart, Lung, and Blood Institute (NHLBI), 1995) In 2010, PCV13 was 
introduced for routine vaccination of children. Studies have reported a significant decline 
in IPD cases caused by PCV13 serotypes, but children with comorbidities are still at 
higher risk for IPD. (Yildirim et al., 2014) The impact of conjugated pneumococcal 
vaccines on epidemiology of pneumonia in urban, minority children and whether the 
vaccine changes the risk factors for pneumonia are important questions.  This study 
proposes to compare the children with and without pneumonia in the Boston Medical 
Center (BMC) health network and assess the underlying risk factors using conditions as 
defined by The Committee on Infectious Diseases of the American Academy of 
Pediatrics (AAP). (Pickering, Baker, & Kimberlin, 2012)  
Through this study, we wish to better understand the factors associated with 
pneumococcal diseases. We hope that the results will contribute to developing and 
evaluating preventive measures for IPD in at-risk and high-risk children. 
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METHODS 
 
Study Design 
Data source: This study used the extensive clinical data available within the 
Massachusetts Health Disparities Repository (MHDR).  For over a decade, Boston 
Medical Center (the largest safety net hospital in New England) and its affiliated 
Community Health Centers have successfully used and maintained a network of 
electronic health record (EHR) systems. Data from these systems have recently been 
integrated and linked to administrative and financial data to create a community health 
research data repository, “The Massachusetts Health Disparities Repository (MHDR).” 
The system uses open-source software (www.i2b2.org) in broad use across the United 
States, and contains over 700 million clinical data elements for over 1.4 million 
individuals and 80,000 primary care patients under the age of 18 years old. MHDR data 
are de-identified but include census tract of residence to allow the study of health 
outcomes by neighborhood. Using existing procedures, we extracted all relevant data for 
the target cohort of children and transferred these data to the secure research “workspace” 
for analysis.    
 
Study Population 
Children under 7 years of age within the I2B2 database who were enrolled for at 
least one full calendar year in either of the two study periods (2007 – 2009 or 2011 – 
2013) were targeted in this study.  
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Due to the large number of candidates, a representative random sample of 300 
patients was selected: 150 patients without pneumonia and 150 patients with pneumonia. 
The information reviewed included: diagnoses, procedures, encounters, labs, vitals, 
medications, clinical notes, immunization records, x-rays, and demographics. The secure 
link table within the BMC-CDW was used to look at medical record of potential patients 
and review chart information. This study was approved by the Institutional Review 
Boards (IRB) of Boston University Medical Center. 
 
Data Analysis 
The categories of the analysis included: 1) diagnoses and problems; 2) medication 
prescriptions (coded using RxNorm coding system); 3) visit types (Inpatient, Emergency, 
and all Ambulatory); 4) lab results; 5) clinical observations (including immunizations). 
The clinical observations included patient assessment and medical history over time as 
well as conditions and concerns during each visit. The International Classification of 
Diseases, 9th Revision (ICD9) code sets for pneumonia that have been used in previous 
studies were used to define children with and without pneumonia. (“ICD - ICD-9-CM - 
International Classification of Diseases, Ninth Revision, Clinical Modification,” n.d.) The 
same approach was used to identify children with and without comorbid conditions.  
 
Immune Status 
 Pneumococcal immunization status was determined for each subject. For young 
children under 12 months of age, vaccination with two or more doses of either PCV7 or 
  20
PCV13 was considered immune. For children aged 12 months and older, vaccination was 
considered immune if: 1) vaccinated with three or more doses of either PCV7 or PCV13 
within the first 12 months after birth or 2) vaccinated with at least one dose of PCV7 or 
PCV13 after the first 12 months after birth. Subjects who failed to satisfy these 
requirements were considered to have incomplete vaccination. 
 
Comorbidities 
 Clinical information for each subject was reviewed to identify any underlying 
conditions present. The comorbidities identified are consistent with conditions listed in 
the 2012 Report of the Committee on Infectious Diseases and 2013 ACIP 
recommendations. (Yildirim et al., 2014) Children with conditions listed are 
recommended to receive pneumococcal vaccinations. (Center for Disease Control and 
Prevention (CDC), 2013) The comorbidity classification list for this study includes: 
asthma, biliary atresia, chronic lung disease, chronic renal failure, cochlear implant, 
congenital heart disease, congenital heart disease with chronic lung disease, congenital 
heart disease with asplenia, down syndrome, HIV, hematologic disease on steroids, 
hematologic malignancy, immunocompromised, nephritic syndrome, neuromuscular 
disorders/ seizures, other GI disorders, prematurity/ low birth weight, primary 
immunodeficiency, solid organ malignancy, solid organ transplant, and sickle cell 
disease. 
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 SAS version 9.3.1 software (SAS Institute, Gary, IN) was used for all statistical 
analyses. We used χ2 tests to compare proportions, and t tests or analysis of variance was 
used to compare continuous variables. We considered two-sided p-values less than 0.05 
as statistically significant. 
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RESULTS 
 
Age and Gender 
From the I2B2 database of patients under the age of 7 years who were enrolled for 
at least one full calendar year in either of the two study periods (2007 – 2009 or 2011 – 
2013), 150 patients with pneumonia and 150 patients without pneumonia were selected 
randomly. Of the randomly chosen patients, our study population consisted of a total of 
143 girls and 157 boys. In our population, the proportion of males was higher among 
children with pneumonia (54.7% male, 45.3% female) compared to the group of children 
without pneumonia (50% male, 50% female), but these values are not statistically 
different (χ2 value 0.65; p-value 0.42). Boys have 1.21 times the odds of having 
pneumonia compared to girls, but it is not statistically significant (95% CI 0.77 – 1.89; p-
value 0.41) (Table 3).  
The ages of our entire study population ranged from 0.0 months to 102.5 months. 
The mean age for children with pneumonia (age at diagnosis) was 38.9 (± 27.7) months, 
whereas the mean age for children without pneumonia was 35.0 (± 31.2) months. We 
found that children with pneumonia were 3.9 (95% CI 2.84 – 10.57) months older than 
children without pneumonia, but this difference in mean age was not statistically 
significant (t-value -1.14) (Table 3).  
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Race 
 Information on race of our study population was available for 284 of 300 (94.7%) 
children. We found that black/African-Americans made up the largest proportion among 
both patients with pneumonia (64%) and patients without pneumonia (62.7%). The 
second largest group consisted of Hispanic/Latino/Spanish children, 23 (15.3%) children 
among patients with pneumonia and 18 (12.0%) children among patients without 
pneumonia. This was followed by white children, 14 (9.3%) children among patients with 
pneumonia and 11 (7.3%) children among patients without pneumonia. The number of 
children with pneumonia was higher than those without pneumonia among black/African-
American, Hispanic/Latino/Spanish, white, and Asian children, while the opposite was 
true for Middle Eastern and children included in the ‘other’ category. The difference in 
these values, however, was not statistically significant (χ2 value 6.03; p-value 0.64) 
(Table 4). 
 
Ethnicity 
 Information on ethnicity was available for 150 patients with pneumonia and 148 
patients without pneumonia. Of the 298 patients with known ethnicity information, 257 
(86.2%) children were not Hispanic/Latino/Spanish, and 41 (13.8%) children were 
Hispanic/Latino/Spanish. 16.7% of children with pneumonia were of Hispanic origin, 
whereas 10.8% of the children without pneumonia were Hispanic. The odds of having 
pneumonia among children who are not of Hispanic origin were approximately 40% less 
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compared to children of Hispanic race (OR 0.61; 95% CI 0.31 – 1.19; p-value 0.14) 
(Table 5). 
 
Language 
 The most common language spoken by the children of our study population was 
English, 65.3% among those with pneumonia and 62% among those without pneumonia. 
This was followed by Haitian Creole (16.7% of children with pneumonia, 19.3% of 
children without pneumonia) and Portuguese Creole/Cape Verdean (3.3% of children 
with pneumonia, 6.7% of children without pneumonia). Compared to the children without 
pneumonia, a larger number of children with pneumonia spoke English, Spanish, Somali, 
Ethiopia (Tigrinian), and other. The difference in these values, however, was not 
statistically significant (χ2 value 11.2; p-value 0.52) (Table 6). 
 
Immune Status 
 Information on pneumococcal immunization for IPD was available for 181 of 300 
(60.3%) children. Of the 181 children with full immunization information, an overall of 
30 children (16.6%) had failed to receive enough vaccination to be considered immune.  
Children with pneumonia and children without pneumonia did not differ statistically in 
terms of PCV immune status (16.7% vs 16.4%, respectively). Pneumonia was reported in 
60% of the 30 patients with incomplete vaccination.  
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Comorbidities 
 Of 300 children in our study group, 120 children (40%) were found to have at 
least one underlying clinical condition. Comorbidities were more common among 
children with pneumonia than those without pneumonia; 76 (50.7%) cases were found to 
have at least one underlying condition, whereas among children without pneumonia, 44 
(29.3%) cases had at least one underlying clinical condition (χ2 value 14.2; p-value 
<0.001). Children with underlying conditions were 2.47 times more likely to have 
pneumonia compared to children without any underlying comorbidities (OR 2.47, 95% 
CI 1.54 – 3.98) (Table 7a).  
 Among 120 children with comorbidities, 125 conditions were reported. The most 
common underlying condition in our study population was asthma, which was reported in 
approximately a third of the children with pneumonia (31.1%), and in more than half of 
the children without pneumonia (54.5%). This was followed by prematurity/ low birth 
weight, 22.9% of children with pneumonia and 11.7% of children without pneumonia. 
Among children with pneumonia, neuromuscular disorder was another common 
condition (20.8%). Among children without pneumonia, sickle cell disease and 
congenital heart disease were more common (11.7%, 5.2%, respectively) compared to 
children with pneumonia (4.2%, 2.1%, respectively) (Table 7b). 
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Table 3. Number and proportion of children under 7 years of age with and without 
pneumonia, by age and gender 
 
  With pneumonia 
Without 
pneumonia 
Χ2* p-value**   n (%) n (%) 
Mean Age (months) 38.9 ± 27.7 35.0 ± 31.2 - 0.14 
Gender         
Female 68 (45.3%) 75 (50.0%) 
0.65 0.42 
Male 82 (54.7%) 75 (50.0%) 
Total 150 150     
* Chi-square statistics, **P values <0.05 were accepted as statistically significant 
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Table 5. Number and proportion of children under 7 years of age with and without 
pneumonia, by ethnicity 
 
 
 
 
 
 
 
Ethnicity 
  
With 
pneumonia 
Without 
pneumonia 
Χ2* p-value** n (%) n (%) 
Hispanic/Latino/Spanish 25 (16.7) 16 (10.8) 
2.15 0.14 
Not 
Hispanic/Latino/Spanish 125 (83.3) 132 (89.2) 
Total 150 148 
    
* Chi-square statistics, **P values <0.05 were accepted as statistically significant 
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Table 7a. Number and proportion of children under 7 years of age with and without 
pneumonia, by presence of comorbidity 
 
Comorbidity 
  
With 
pneumonia 
Without 
pneumonia 
Χ2* p-value**   n (%) n (%) 
Underlying Conditions 76 (50.7) 44 (29.3) 
14.20 <0.001 
No Underlying 
Conditions 74 (49.3) 106 (70.3) 
Total 150 150 
    
* Chi-square statistics, **P values <0.05 were accepted as statistically significant 
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DISCUSSION 
 
 Introduction of PCV7 and PCV13 in the United States has led to a dramatic 
decrease in IPD cases caused by vaccine serotypes in both children and adults. However, 
studies have reported that IPD incidence rates still remain high among those with 
underlying conditions. A significant proportion of children in our study population had at 
least one underlying condition, and children with underlying clinical conditions were at 
nearly 2.5 times higher risk of developing pneumonia compared to children without 
comorbidities. Our study also shows that a nearly 2-fold higher proportion of children 
with pneumonia was found to have neuromuscular disorder or was born prematurely 
compared to otherwise healthy children without pneumonia. This suggests that these 
conditions place children at greater risk for pneumonia, but further studies will be needed 
with a larger study population to confirm the association between pneumonia and these 
underlying conditions. Our data support findings of recently published reports that 
conclude that children with underlying chronic conditions are still at higher risk for IPD 
compared to healthy children, possibly due to the reduced effectiveness of vaccines in 
these children or due to the higher susceptibility of these children to less virulent 
serotypes not included in PCV vaccines. (Tamar Pilishvili et al., 2010) 
  In our study population, we found that a higher proportion of children with 
pneumonia was male compared to children without pneumonia, but the difference was 
not statistically significant. Previous studies have reported higher incidence rates of IPD 
in male children, suggesting that there is a possibility that we may have missed a 
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significant value due to the small size of our study population. (Levine et al., 1999; 
Nuorti et al., 2000; Tamar Pilishvili et al., 2010) 
 We found that black/African-Americans made up the largest proportion among 
both patients with pneumonia and patients without pneumonia in our study, followed by 
Hispanic/Latino/Spanish, white, and Asian populations. The demographics of the hospital 
could have contributed to this data. According to the Boston Medical Center Community 
Health Needs Assessment in 2013, approximately 70% of the hospital’s patients are 
racial and ethnic minorities, with 73% coming from underserved populations. (Health 
Resources in Action, 2013) The proportion of children with pneumonia was greater in the 
four racial groups compared to that of children without pneumonia, but the difference 
was statistically not significant. Many studies have reported racial disparity in IPD cases, 
with the highest incidence rates occurring in black/African-American population. (Center 
for Disease Control and Prevention (CDC), 2010; Nuorti et al., 2000; Robinson et al., 
2001) Again, we may have missed a significant association in our study due to the small 
sample size. Our study, however, shows that children of Hispanic origin are 1.65 times 
more likely to have pneumonia compared to children who are not 
Hispanic/Latino/Spanish. This supports earlier findings that the second highest IPD 
incidence rates are occurring in Hispanic children, following black/African-American 
population. (Hsu, Shea, Stevenson, Pelton, & Massachusetts Department of Public 
Health, 2010)  
 According to a report by the National Foundation for Infectious Diseases and the 
National Coalition for Adult Immunization (2002), minority populations may be at higher 
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risk for pneumococcal diseases due to low immunization rates. Pneumococcal 
immunization records of our study population were used to determine the association of 
vaccination with pneumonia cases. Children with pneumonia and children without 
pneumonia did not differ statistically in terms of complete vaccination, but the 
vaccination information was available for only 60.3% of the study population. In order to 
conclusively determine the association between immune status and pneumonia cases, 
further study with a larger sample size is needed. 
 
Limitations of the Study  
 There are several limitations in our study. First, our study population consisted of 
300 children (150 children with pneumonia, 150 children without pneumonia), and the 
sample size was too small to have sufficient statistical power. Statistical significance will 
be directly impacted with sample size (n). A larger study population will be needed in 
future studies to reduce sampling error and determine the association of risk factors with 
pneumonia cases with more precision. Another limitation is the lack of information for 
immune status. Approximately 40% of the pneumococcal vaccination data were not 
available, further reducing the sample size.  
 In our study, only a small portion of the study population was vaccinated with 
PCV13 (it was introduced in the summer of 2010). In the future studies, a larger number 
of subjects with PCV13 vaccination may be used in order to better compare the risk 
factors of the group with PCV7 vaccination with the risk factors of the group with 
PCV13 vaccination.  
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Conclusion 
 In our study, we found that there is a significantly higher risk of developing 
pneumonia among children with at least one underlying chronic condition compared to 
children with no comorbidities. We also found that ethnicity is associated with 
pneumonia cases, with children of Hispanic origin having a significantly increased risk of 
developing pneumonia compared to children of other ethnicity. Ongoing studies 
involving larger study population will be necessary in order to more accurately assess the 
risk factors for pneumonia affecting children in Massachusetts.
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